This trial is testing a new way to treat cancer using the patient's own immune cells.
6 Primary · 0 Secondary · Reporting Duration: 3 years
Experimental Treatment
63 Total Participants · 1 Treatment Group
Primary Treatment: autologous CD19-directed chimeric antigen receptor (CAR) T-cells · No Placebo Group · Phase 1 & 2
Age 2 - 70 · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: